Kana Yokoji

Real‐World Evidence of Treatment Patterns, Time to Real‐World Progression, and Overall Survival of Patients With Testicular Germ Cell Tumors Receiving Palliative Chemotherapy in the United States

Darren Richard Feldman, Patrick Gagnon‐Sanschagrin, Jessica Maitland, Kana Yokoji et autres

INTRODUCTION: Patients with relapsed/refractory (R/R) testicular germ cell tumor (GCT) progressing after salvage chemotherapy only have palliative therapeutic options. Real-world data on this population are needed. METHODS: Adult men with testicular GCT receiving palliative chemotherapy in the United States were identified in …

us, ca (code pays fourni par la source)

HSD106 PATHWAYS OF CARE AND ACCESS TO RIFAXIMIN POST-DISCHARGE IN MEDICARE-INSURED PATIENTS WITH OVERT HEPATIC ENCEPHALOPATHY

Arun B. Jesudian, Patrick Gagnon‐Sanschagrin, Rebecca Bungay, Kaitlyn Easson et autres

us (code pays fourni par la source)

EE229 CAREGIVER BURDEN AND SOCIOECONOMIC IMPACT OF HE AND OHE AMONG INDIVIDUALS CARING FOR PATIENTS WITH CIRRHOSIS

Arun B. Jesudian, Debbie Goldschmidt, Patrick Gagnon‐Sanschagrin, Aditi Shah et autres

us (code pays fourni par la source)

Antipsychotic Treatment Pathways, Real-World Adherence, Healthcare Resource Utilization, and Healthcare Costs Among Patients With Schizophrenia Treated With Once-Monthly, Once-Every-Three-Months, and Once-Every-Six-Months Paliperidone Palmitate in the United States

Laura Morrison, Dominic Pilon, Arthur Voegel, Lilián Díaz et autres

PURPOSE: Patients with schizophrenia can initiate once-every-6-months paliperidone palmitate (PP6M), currently the longest dosing interval long-acting injectable (LAI) antipsychotic (AP), following adequate treatment with once-every-3-months paliperidone palmitate (PP3M) or once-monthly paliperidone palmitate (PP1M). However, limited real-world evidence exists describing the AP treatment …

ca, us (code pays fourni par la source)

Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors

Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty et autres

INTRODUCTION: Patients with active psoriatic arthritis (PsA) initiating guselkumab are nearly two times more likely to remain persistent with on-label therapy at 12 months compared to those initiating subcutaneous (SC) interleukin-17A inhibitors (IL-17Ai). In this real-world study, on-label treatment persistence at 24 …

us (code pays fourni par la source)

On-Label Treatment Persistence Through 24 Months Among Patients with Active Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Tumor Necrosis Factor Inhibitors

Philip J. Mease, Jessica A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty et autres

INTRODUCTION: There is limited prior literature comparing long-term treatment persistence between guselkumab and subcutaneous (SC) tumor necrosis factor inhibitors (TNFi) in biologic-naïve and biologic-experienced patients with active psoriatic arthritis (PsA). This study compared on-label persistence through 24 months between patients with active …

us (code pays fourni par la source)

1125P Beyond checkpoint inhibitors: Real-world (rw) treatment (tx) practices and clinical outcomes in advanced/recurrent endometrial cancer (a/r EC) post-immune checkpoint inhibitor (ICI) tx

Bhavana Pothuri, Esteban Carlos Serra, Jerome Bedard, Kana Yokoji et autres

us, gb (code pays fourni par la source)

EE375 Real-World Adherence, Healthcare Resource Utilization, And Costs Among Patients With Schizophrenia Utilizing Once-Monthly, Once-Every-Three-Months, And Once-Every-Six-Months Paliperidone Palmitate in the United States

Charmi A. Patel, Dominic Pilon, Laura Morrison, Arthur Voegel et autres

us (code pays fourni par la source)

EE220 Impact of Post-Discharge Rifaximin Use Following an Overt Hepatic Encephalopathy (OHE) Hospitalization on Annual Rates of OHE Rehospitalization in the United States

Arun B. Jesudian, Patrick Gagnon‐Sanschagrin, Rebecca Bungay, Kaitlyn Easson et autres

us (code pays fourni par la source)

ABS1075 ON-LABEL PERSISTENCE THROUGH 24 MONTHS IN PATIENTS WITH PSORIATIC ARTHRITIS USING GUSELKUMAB OR SUBCUTANEOUS INTERLEUKIN-17A INHIBITORS

Philip J. Mease, J. A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty et autres

POS1025 ON-LABEL PERSISTENCE THROUGH 24 MONTHS AMONG PATIENTS WITH PSORIATIC ARTHRITIS INITIATING GUSELKUMAB OR SUBCUTANEOUS TNF INHIBITORS

Philip J. Mease, J. A. Walsh, Timothy P. Fitzgerald, Soumya D. Chakravarty et autres

Background: In a previous claims-based analysis of patients (pts) with psoriatic arthritis (PsA), those receiving guselkumab (GUS; a fully human IL-23p19-subunit inhibitor) were ~3x more likely to remain persistent through 12 months (M) versus those initiating their first subcutaneous (SC) tumor necrosis …

us (code pays fourni par la source)

Tu1539: IMPACT OF RIFAXIMIN AND LACTULOSE TREATMENT PATTERNS ON 30-DAY REHOSPITALIZATION RISK IN OVERT HEPATIC ENCEPHALOPATHY: A CLAIMS-BASED ANALYSIS

Arun B. Jesudian, Patrick Gagnon‐Sanschagrin, Rebecca Bungay, Kaitlyn Easson et autres